The Globe and Mail reports in its Tuesday edition that Canada's medical-cannabis companies say their American counterparts will continue to be stifled under the upcoming Trump presidency. The Globe's Mike Hager expects Canadian growers to scale up to meet the domestic demand for recreational pot while preparing to enter the U.S. market as global industry leaders once prohibition there ends. While one in five Americans will soon live in jurisdictions that have legalized recreational cannabis, president-elect Donald Trump has said he is against changing a federal law prohibiting the drug. That means the growth of U.S. companies will likely be stymied over the next four years by a number of barriers, including the inability to transfer the drug across state lines, blacklisting by risk-averse banks and having limited access to capital from institutional investors. Mr. Trump has said he is "100 per cent" in favour of medical marijuana. However, even if a Republican-dominated government reclassifies cannabis, firms would likely face years meeting a host of strict regulatory hurdles from the U.S. Food and Drug Administration before they can sell it as a medicine across the country.